

Tuesday 13th May 2025



Today's issue of PD

Pharmacy Daily today features three pages of industry news, plus a full page from **Chemsave**.

Do the maths

ALIGNING with Chemsave delivers bottom-line benefits for your pharmacy.

If you are looking to buy a pharmacy, consider joining Chemsave's Wealth 100 Club - membership is free.

Learn more on page four.

GP waiting times

AROUND 15% of Australians waited up to an hour past their scheduled GP appointment time, a new Money.com.au study has revealed.

The survey of 1,000 Aussies found only 10% of respondents saw their GP within 10 minutes, while 36% waited up to 30 minutes.

Money.com.au GM of Health Insurance, Chris Whitelaw, said patients can help by booking a longer consultation if needed.

Refreshed Ministry welcomed

MARK Butler has been reappointed Minister for Health and Aged Care in a cabinet reshuffle yesterday, with the pharmacy sector welcoming his continuation in the role.

"The Guild and community pharmacy looks forward to working with Minister Butler and his team to continue delivering for all Australian patients," said National President Pharmacy Guild of Australia, Professor Trent Twomey.

Twomey pointed out that Butler had "worked hard to put patients at the heart of his work", particularly with the recent move to make medicine more affordable.

"Continuity will ensure the necessary reforms to healthcare, including expanding the range of services offered in pharmacy, can be taken forward at pace.

"There were a lot of reviews and recommendations in the first term - now is the time to put these into practice in partnership with industry, healthcare professionals and experts," Twomey said.

In other appointments, Rebecca White is now Assistant Minister for Health and Aged Care, replacing Ged Kearney; Emma McBride retained her role as Assistant

Cetaphil Pro

Soothe &

Helps repair

barrier after

Eczema Prone

Repair Cream

weakened skin

1 use to relieve

dry itchy skin.2

eczema association Minister for Mental Health, Suicide Prevention and Rural and Regional Health; and Olympic sport shooter Dan Repacholi was appointed Special Envoy for Men's Health.

Professor Twomey said he was looking forward to continuing to work closely with fellow pharmacist Emma McBride to deliver regional and rural healthcare, and also with Dan Rapacholi in his new role.

Advanced Pharmacy Australia (AdPha) Chief Executive Kristin Michaels also extended congratulations to Minister Butler and others in the health and aged care arena.

"Minister Butler has consistently championed pharmacy's evolving role in delivering better patient outcomes, and we are confident his leadership will continue to drive bold, innovative reform through the response to the Scope of Practice Review and upcoming Pharmacy Programs Agreement," Michaels said.

"We look forward to working with the team to lead the critical work of improving equitable access to medicines and pharmacy care for all Australians across our diverse healthcare system.

"I'd also like to sincerely thank outgoing Assistant Minister Ged Kearney for her leadership and, in particular, her instrumental role in delivering the National Climate and Health Strategy," Michaels added.

The National Rural Health Alliance (NRHA) said it was looking forward to working with the ministry as it acts on the recommendations of key reviews undertaken in the last term of government.

NRHA also pointed to Assistant Minister White's long-standing association with rural communities in welcoming her appointment. KB


Regional support

IMPROVEMENTS are needed in the level of contraceptive care provided to teenagers in regional and rural areas, a new study from Monash University has found.

The study interviewed 18 GPs, who agreed higher rates of teenage pregnancy in their region were related to limited knowledge of and access to contraception, along with high costs and limited providers.



Making healthy connections



A hub for pharmacy apps and integrations

Learn more

Cetaphil Pro Eczema Prone Itch Relief Gel

Clinically proven to provide itch relief in 30 seconds and lasts up to 12 hours.¹

Innovative Cool-Touch Applicator

Annual financial contribution to

Annual financial contribution to EAA.

1. Galderma data on file [GLI.04.US.035]. 2. Galderma data on file [RD.53.SPR.205147]



For effective cleaning between teeth









Tuesday 13th May 2025





ORDER HERE

Credentialing transition extended

THE Pharmacy Programs
Administrator has extended
transition arrangements for
pharmacists delivering Medication
Management Review (MMR) and
Aged Care On-site Pharmacist
(ACOP) services.

The MMR transition is extended to 31 Dec 2025, and the ACOP transition is extended to 30 Jun 2026.

This extension means pharmacists can continue delivering services using their existing Medication Review Numbers (MRNs) while they transition to new credentialing requirements.

The previous MMR transition deadline was 30 Jun, after which current MRNs were to become invalid (*PD* 19 Feb).

The Pharmaceutical Society of Australia (PSA) welcomed the announcement, with PSA Consultant Pharmacist Adviser Debbie Rigby noting the peak body's support for consultant pharmacists through the transition to new credentials.

"We've heard your concerns and have advocated for more time, particularly in ACOP roles," she said.

"I'm pleased there has been a time extension to complete the ACOP credential whilst continuing to implement this valuable service in aged care facilities."

Chair of the PSA's Consultant Pharmacists Community of Specialty Interest Deborah Hawthorne said the extension was a result of PSA's ongoing advocacy for consultant pharmacists.

"This decision provides muchneeded certainty for consultant pharmacists, ensuring they can continue delivering critical patient care while completing their credentialing," Hawthorne said.

"We encourage all pharmacists to submit their evidence for recognition of prior learning (RPL) as soon as possible.

"We expect this will be the final extension, so it's your last real opportunity to make the most of the RPL pathway," she concluded.

Trump's pharma executive order fear

US PRESIDENT Donald Trump has signed an executive order directing pharmaceutical companies to reduce US drug prices to align with what other countries pay, causing sales turmoil in pharma stocks and raising concerns in other countries.

The order gives drug companies price targets in the next 30 days, and notes that further action will be taken to lower prices if companies do not make "significant progress" toward those goals.

Trump told a press conference he is seeking cuts of between 59% and 90%.

"Everybody should equalise, everybody should pay the same price," he said.

The United States pays the highest prices for prescription drugs, often nearly three times more than other developed nations.

"The US has for too long

turned its back on Americans, who unwittingly sponsor both drug manufacturers and other countries," the order states.

In a system akin to Australia's Pharmaceutical Benefits Scheme, the executive order directs the Health and Human Services Secretary, currently Robert F Kennedy Jr, to have the government buy prescription drugs directly from the manufacturers at "the mostfavoured nation price", which means the lowest price other countries are paying.

By reducing the amount that drug companies can charge Americans, Trump expects pharmaceutical companies will compensate by charging the rest of the world - including Australia - higher prices.

An early warning of the move (**PD** 12 May) sent pharma stocks tumbling, but they rallied when it appeared that the order was not as bad as feared.



ALL-IN-ONE 8-HOUR RELIEF¹ Systane® COMPLETE Preservative-Free:

 Clinically proven to relieve all types of dry eye for 8 hours¹

 Protects and replenishes all layers of the tear film¹



Powered by HP-Guar's hydrophilic meshwork in the muco-aqueous layer, creating a protective elastic matrix^{1,2}

Recommend Systane® COMPLETE for Excellent Relief



ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE.

References: 1. Silverstein et al. Clin Ophthalmol. 2020;14:3167-3177.
2. Springs CL. Adv Ther. 2010 Oct;27(10): 681-90. ⊚2025 Alcon Laboratories Pty Ltd. AUS: 1800 224 153; Auckland NZ: 0800 101 106. ANZ-SYX-2500005.

SYSTANE.COM.AU

Alcon



Tuesday 13th May 2025

Get your own copy of **Pharmacy Daily**

CLICK FOR YOUR FREE SUBSCRIPTION





Dispensary Corner

US CUSTOMS and Border Protection (CBP) officers at the El Paso crossing apprehended a woman carrying a package of fentanyl in her vagina.

After being selected for a secondary exam at the border, the woman admitted to having a foreign object hidden inside her body, and was taken to a medical facility where it was confirmed and removed.

As you'd no doubt appreciate, it would have been catastrophic had the packaging failed.

CBP El Paso Port Director Ray Provencio said, in something of an understatement, "It is best to not engage in smuggling activity, but especially this form...It is risky on many levels."

The incident comes two weeks after El Paso border forces found more than 5kg of fentanyl tablets and powder hidden in the battery compartment of a motor scooter, while another haul was found within the frame of a bicycle.

More than 150 Americans die each day from fentanyl and synthetic opioid overdose.

Battle of the heavyweights

A NEW head-to-head study of tirzepatide (Mouniaro) versus semaglutide (Ozempic/Wegovy) for weight loss in people living with obesity, but not diabetes, has found that Mounjaro resulted in greater weight loss over 72 weeks than Wegovy.

The study, which was sponsored by Mounjaro manufacturer Eli Lilly, was presented at this year's European Congress on Obesity and published in NEJM.

It included 750 patients who were randomised to receive either Mounjaro or Wegovy, with those on Mounjaro achieving an average weight loss of 20.2%, compared with 13.7% average weight loss for Wegovy.

In other results, 65% of participants treated with Mounjaro lost at least 15% of their body weight compared with 40% of those on Wegovy, and attained an average waist circumference reduction of 18cm compared with 13cm for Wegovy.

Adverse events reported during the trial were similar for both medications and related primarily to gastrointestinal symptoms, which were generally mild to moderate in severity.

Around 6-8% of participants



dropped out due to side effects.

While both drugs are highly effective obesity management medications, this new study is the first to test, in a head-to-head trial, their efficacy and safety in adults with obesity but without type 2 diabetes.

'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before," said study lead, Professor Louis Aronne.

"The head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management," he added.

Read the study HERE. KB

McQueen to speak at Connect

THE keynote speaker for Pharmacy Connect 2025 has been announced, with renowned futurist, multiaward-winning speaker, and best-selling author, Michael McQueen, to take the stage.

Widely recognised for his ability to help organisations stay ahead of the curve, McQueen will deliver a session on 'Preparing now for what's next - how to thrive in an age of uncertainty'.

He will explore how to thrive amid rapid change, offering attendees unique insights into future trends and practical strategies for success.

"Michael's expertise in trend forecasting and his ability to provide actionable strategies for navigating uncertainty will be immensely beneficial to delegates at Pharmacy Connect 2025," said Conference Convenor, Kos Sclavos.

"His session will give delegates tools to tackle challenges both personally and professionally," he added.

The conference takes place 03-05 Sep in Sydney - CLICK **HERE** for earlybird registration.

Save time. Save Money.

Time to rethink your dispensary set-up?

The latest in pharmacy robotic automation from Willach Pharmacy Solutions. No matter the size of your pharmacy, contact us for a confidential discussion to explore the options available.



Willach Pharmacy Solutions

willach.com.au

[03] 9429 8222

info@willach.com.au



www.pharmacydaily.com.au

Pharmacy Daily is part of the **Business Publishing Group family** of publications.

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor - Karina Bray Deputy Editor - Matt Lennon Journalists - Adam Bishop, Myles Stedman, Janie Medbury Editor-at-large - Bruce Piper

Associate Publisher - Jo-Anne Hui-Miller Editorial Director - Damian Francis

ADVERTISING AND MARKETING **Head of Sales & Marketing**

advertising@pharmacvdailv.com.au

GENERAL MANAGER & PUBLISHER

ACCOUNTS

accounts@traveldaily.com.au

Suite 1, Level 2, 64 Talavera Rd Macquarie Park NSW 2113 Australia Tel: 1300 799 220 (+61 2 8007 6760)


info@pharmacydaily.com.au



Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Damian Francis.

Do The Math(s)!





YOUR BIG SAVINGS CHEMIST



LOOKING TO BUY A PHARMACY?

0% DEPOSIT
100% OWNERSHIP

BECOME A FREE CLUB MEMBER TODAY

> A CHEMSAVE INITIATIVE



VIC, SA, WA, TAS & NT

Michael Story 0425 820 160 michaelstory@chemsave.com.au



NSW, QLD & ACT

Simon Metcalfe 0499 208 182 simonmetcalfe@chemsave.com.au